AJP - GI Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Gastrointest Liver Physiol 285: G919-G928, 2003. First published July 3, 2003; doi:10.1152/ajpgi.00205.2003
0193-1857/03 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
285/5/G919    most recent
00205.2003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (18)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Farah, M.
Right arrow Articles by Salh, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Farah, M.
Right arrow Articles by Salh, B.

MUCOSAL BIOLOGY

5,6-Dichloro-ribifuranosylbenzimidazole- and apigenin-induced sensitization of colon cancer cells to TNF-{alpha}-mediated apoptosis

Myriam Farah, Kuljit Parhar, Maryam Moussavi, Sharlene Eivemark, and Baljinder Salh

The Jack Bell Research Centre, Vancouver, British Columbia, Canada V6H 3Z6

Submitted 6 May 2003 ; accepted in final form 24 June 2003

Tumor necrosis factor-{alpha} (TNF-{alpha}) is a multifunctional cytokine involved in the expression of many genes integral to the inflammatory response. In addition, it activates both apoptotic and survival pathways, the latter being mediated through the activation of the transcription factor nuclear factor-{kappa}B (NF-{kappa}B). Protein kinase CK2, a serine-threonine kinase that is universally upregulated in human malignancies, may be involved at multiple levels in this process. However, its role in mediating a survival response within colon cancer cells remains incompletely understood. Here we report that inhibition of CK2 in HCT-116 and HT-29 cells with the use of two specific CK2 inhibitors, 5,6-dichloro-ribifuranosylbenzimidazole (DRB) and apigenin, effected a synergistic reduction in cell survival when used in conjunction with TNF-{alpha}. Furthermore, there was a demonstrable synergistic reduction in colony formation in soft agar with the use of the same combinations. Western blot analysis showed that poly-ADP ribose polymerase and procaspase-3 cleavage complemented the fluorescence-activated cell sorter analysis findings of significantly increased subdiploid DNA-containing cell populations using these conditions. Remarkably, these events occurred in the absence of any reduction in the expression of the Bcl-2 family members Bcl-2, Mcl-1, and Bcl-xL or any change in the proapoptotic molecules Bad or Bax. One-hybrid NF-{kappa}B promoter assays utilizing a Gal4-p65 transactivation domain construct revealed that the TNF-induced transactivation was inhibited by both DRB and apigenin. This was associated with a concomitant reduction in the expression of a recognized anti-apoptotic NF-{kappa}B target, manganese superoxide dismutase, demonstrated by Q-PCR. Our findings indicate a potentially novel strategy for the treatment of colon cancer, one that targets CK2 simultaneous with TNF-{alpha} administration.

CK2; tumor necrosis factor-{alpha}; apoptosis; nuclear factor-{kappa}B; manganese superoxide dismutase



Address for reprint requests and other correspondence: B. Salh, Division of Gastroenterology, Univ. of British Columbia, 100-2647 Willow St., Vancouver BC V5Z 3P1, Canada.




This article has been cited by other articles:


Home page
Exp. Biol. Med.Home page
G. Sethi, B. Sung, and B. B. Aggarwal
Nuclear Factor-{kappa}B Activation: From Bench to Bedside
Experimental Biology and Medicine, January 1, 2008; 233(1): 21 - 31.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Van Waes
Nuclear Factor-{kappa}B in Development, Prevention, and Therapy of Cancer
Clin. Cancer Res., February 15, 2007; 13(4): 1076 - 1082.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
A. Hubert, S. Paris, J.-P. Piret, N. Ninane, M. Raes, and C. Michiels
Casein kinase 2 inhibition decreases hypoxia-inducible factor-1 activity under hypoxia through elevated p53 protein level
J. Cell Sci., August 15, 2006; 119(16): 3351 - 3362.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Yu, J. Yeh, and C. Van Waes
Protein Kinase Casein Kinase 2 Mediates Inhibitor-{kappa}B Kinase and Aberrant Nuclear Factor-{kappa}B Activation by Serum Factor(s) in Head and Neck Squamous Carcinoma Cells.
Cancer Res., July 1, 2006; 66(13): 6722 - 6731.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2003 by the American Physiological Society.